Alice S. Mims, MD, of The Ohio State University’s James Comprehensive Cancer Center, provided an overview of current AML treatment options, such as FLT3 and IDH inhibitors, while also highlighting promising emerging strategies like menin inhibitors, antibody-drug conjugates, immune-based approaches (including CAR T-cell and NK cell therapies), and evolving classifications impacting diagnosis and prognosis. She guided listeners through both the latest approved therapies and clinical trial developments that may shape the future of AML care.